Processa Pharmaceuticals, Inc.
PCSANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for PCSA. That does not mean none is planned.
Get an email about PCSA's next catalysts
Track Processa Pharmaceuticals (PCSA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
PCSA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
PCS12852
Gastroparesis
PCS6422 and capecitabine
Breast Cancer
RX-3117
Metastatic Pancreatic Cancer
PCS499
Necrobiosis Lipoidica
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PCS12852 | Phase 2 | Gastroparesis | - | - |
PCS6422 and capecitabine | Phase 2 | Breast Cancer | - | - |
RX-3117 | Phase 2 | Metastatic Pancreatic Cancer | - | - |
PCS499 | Phase 2 | Necrobiosis Lipoidica | - | - |
Frequently asked questions
What is in Processa Pharmaceuticals, Inc.'s drug pipeline?β
CatalystAlert tracks 4 drug candidates in Processa Pharmaceuticals, Inc.'s (PCSA) pipeline across Phase 2. Its lead program is PCS12852 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Processa Pharmaceuticals, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Processa Pharmaceuticals, Inc. (PCSA) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track PCSA biotech catalysts?β
Add PCSA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Processa Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
